
News|Articles|July 17, 2025
Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy?
Advertisement
Advertorial:
The triad of inflammation, neuropathy, and vasculopathy plays a key role in the development and progression of diabetic retinopathy (DR). Dr. Varun Chaudhary and Dr. Patrick Bussfeld, discuss how retinal non-perfusion (RNP) specifically drives disease progression and why it should be explored as a treatment target.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: New horizons in research and risk management for ROP
2
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
3
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
4
FLORetina 2025: Artificial intelligence at the frontlines of ROP care
5












































